News

The initial Phase I study, which will be performed by the Children’s Oncology Group (COG) Phase I Consortium that includes 20 clinical COG sites in North America, will

The Commission amended the information regarding SmPCs, dosage adjustments, Posology and method of administration, and therapeutic indication for Aranesp. The CHMP granted positive opinions for all centrally-authorized erythropoiesis

QuantRx and Jant are exploring quantitative point of care technologies in areas of oncology, cardiovascular, and other emerging markets. The technologies are supported by strong IP positions as

The Phase II trial will be an international, multi-centre, randomized, controlled, open label study assessing the efficacy and safety of CTCE-9908 that will include up to 123 patients.

The survey found that many people bought prescription-drugs under the influence of the drug ads, which they otherwise would not have bought. The poll also found that 82%

The budget has reduced customs duty from 15% to 10% for some live-saving medicines and the bulk drugs used in their manufacture, and also exempted them from excise

The PCA3 test measures the expression of prostate cancer gene 3 (PCA3) mRNA in urine samples. PCA3 is specific to the prostate and is significantly up-regulated (60-100 fold)

Under the terms of the collaboration agreement, PolyTherics will explore the biological effects on proteins of Biocompatibles’s proprietary phosphorylcholine drug delivery technology. This new study builds on the

The purchase price consisted of cash and debt. Lumar Diagnostic Imaging will operate as a wholly owned subsidiary of Bederra under the new name of Lumar Imaging. Graham